523 related articles for article (PubMed ID: 29891528)
1. Advances in Immunotherapy for Metastatic Merkel Cell Carcinoma: A Clinician's Guide.
Paulson KG; Bhatia S
J Natl Compr Canc Netw; 2018 Jun; 16(6):782-790. PubMed ID: 29891528
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy for Merkel Cell Carcinoma.
Nagase K; Narisawa Y
Curr Treat Options Oncol; 2018 Sep; 19(11):57. PubMed ID: 30238195
[TBL] [Abstract][Full Text] [Related]
3. Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapy.
Miller NJ; Church CD; Fling SP; Kulikauskas R; Ramchurren N; Shinohara MM; Kluger HM; Bhatia S; Lundgren L; Cheever MA; Topalian SL; Nghiem P
J Immunother Cancer; 2018 Nov; 6(1):131. PubMed ID: 30482247
[TBL] [Abstract][Full Text] [Related]
4. Scientific and clinical developments in Merkel cell carcinoma: A polyomavirus-driven, often-lethal skin cancer.
Akaike T; Nghiem P
J Dermatol Sci; 2022 Jan; 105(1):2-10. PubMed ID: 34836718
[TBL] [Abstract][Full Text] [Related]
5. Polyomavirus-driven Merkel cell carcinoma: Prospects for therapeutic vaccine development.
Tabachnick-Cherny S; Pulliam T; Church C; Koelle DM; Nghiem P
Mol Carcinog; 2020 Jul; 59(7):807-821. PubMed ID: 32219902
[TBL] [Abstract][Full Text] [Related]
6. Immune Checkpoint Inhibitors and Beyond: An Overview of Immune-Based Therapies in Merkel Cell Carcinoma.
Samimi M
Am J Clin Dermatol; 2019 Jun; 20(3):391-407. PubMed ID: 30784027
[TBL] [Abstract][Full Text] [Related]
7. Merkel Cell Carcinoma in the Age of Immunotherapy: Facts and Hopes.
Colunga A; Pulliam T; Nghiem P
Clin Cancer Res; 2018 May; 24(9):2035-2043. PubMed ID: 29217527
[TBL] [Abstract][Full Text] [Related]
8. Quality Is King: Fundamental Insights into Tumor Antigenicity from Virus-Associated Merkel Cell Carcinoma.
Lahman MC; Paulson KG; Nghiem PT; Chapuis AG
J Invest Dermatol; 2021 Aug; 141(8):1897-1905. PubMed ID: 33863500
[TBL] [Abstract][Full Text] [Related]
9. Updates on Merkel Cell Carcinoma.
Emge DA; Cardones AR
Dermatol Clin; 2019 Oct; 37(4):489-503. PubMed ID: 31466589
[TBL] [Abstract][Full Text] [Related]
10. Merkel Cell Carcinoma from Molecular Pathology to Novel Therapies.
Stachyra K; Dudzisz-Śledź M; Bylina E; Szumera-Ciećkiewicz A; Spałek MJ; Bartnik E; Rutkowski P; Czarnecka AM
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34208339
[TBL] [Abstract][Full Text] [Related]
11. Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA.
Paulson KG; Voillet V; McAfee MS; Hunter DS; Wagener FD; Perdicchio M; Valente WJ; Koelle SJ; Church CD; Vandeven N; Thomas H; Colunga AG; Iyer JG; Yee C; Kulikauskas R; Koelle DM; Pierce RH; Bielas JH; Greenberg PD; Bhatia S; Gottardo R; Nghiem P; Chapuis AG
Nat Commun; 2018 Sep; 9(1):3868. PubMed ID: 30250229
[TBL] [Abstract][Full Text] [Related]
12. Rationale for immune-based therapies in Merkel polyomavirus-positive and -negative Merkel cell carcinomas.
Vandeven N; Nghiem P
Immunotherapy; 2016 Jul; 8(8):907-21. PubMed ID: 27381685
[TBL] [Abstract][Full Text] [Related]
13. Immunobiology of Merkel cell carcinoma: implications for immunotherapy of a polyomavirus-associated cancer.
Bhatia S; Afanasiev O; Nghiem P
Curr Oncol Rep; 2011 Dec; 13(6):488-97. PubMed ID: 21953511
[TBL] [Abstract][Full Text] [Related]
14. Merkel cell carcinoma: Do you know your guidelines?
Miles BA; Goldenberg D;
Head Neck; 2016 May; 38(5):647-52. PubMed ID: 26716756
[TBL] [Abstract][Full Text] [Related]
15. Regression of metastatic Merkel cell carcinoma following transfer of polyomavirus-specific T cells and therapies capable of re-inducing HLA class-I.
Chapuis AG; Afanasiev OK; Iyer JG; Paulson KG; Parvathaneni U; Hwang JH; Lai I; Roberts IM; Sloan HL; Bhatia S; Shibuya KC; Gooley T; Desmarais C; Koelle DM; Yee C; Nghiem P
Cancer Immunol Res; 2014 Jan; 2(1):27-36. PubMed ID: 24432305
[TBL] [Abstract][Full Text] [Related]
16. Current concepts and approaches to merkel cell carcinoma.
Babadzhanov M; Doudican N; Wilken R; Stevenson M; Pavlick A; Carucci J
Arch Dermatol Res; 2021 Apr; 313(3):129-138. PubMed ID: 32666149
[TBL] [Abstract][Full Text] [Related]
17. Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy.
Goh G; Walradt T; Markarov V; Blom A; Riaz N; Doumani R; Stafstrom K; Moshiri A; Yelistratova L; Levinsohn J; Chan TA; Nghiem P; Lifton RP; Choi J
Oncotarget; 2016 Jan; 7(3):3403-15. PubMed ID: 26655088
[TBL] [Abstract][Full Text] [Related]
18. Emerging and mechanism-based therapies for recurrent or metastatic Merkel cell carcinoma.
Miller NJ; Bhatia S; Parvathaneni U; Iyer JG; Nghiem P
Curr Treat Options Oncol; 2013 Jun; 14(2):249-63. PubMed ID: 23436166
[TBL] [Abstract][Full Text] [Related]
19. Recent Insights and Advances in the Management of Merkel Cell Carcinoma.
Banks PD; Sandhu S; Gyorki DE; Johnston ML; Rischin D
J Oncol Pract; 2016 Jul; 12(7):637-46. PubMed ID: 27407160
[TBL] [Abstract][Full Text] [Related]
20. Merkel Cell Carcinoma Therapeutic Update.
Cassler NM; Merrill D; Bichakjian CK; Brownell I
Curr Treat Options Oncol; 2016 Jul; 17(7):36. PubMed ID: 27262710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
